Calissendorff Swarting supports Swedish Orphan Biovitrum AB (publ) (Sobi) legal department with advice and lawyers for a longer period of time. Camilla Appelgren is primarily Calissendorff Swarting’s responsible partner. The assignment involves also Peter Nilsson, Martin Nyberg and other lawyers from the firm.
Sobi is an international specialty healthcare company dedicated to rare diseases with a mission to develop and deliver innovative therapies and services to improve the lives of patients. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm.